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The spike (S) protein of the severe acute respiratory syndrome coronavirus (SARS-CoV) interacts with
cellular receptors to mediate membrane fusion, allowing viral entry into host cells; hence it is recognized as the
primary target of neutralizing antibodies, and therefore knowledge of antigenic determinants that can elicit
neutralizing antibodies could be beneficial for the development of a protective vaccine. Here, we expressed five
different fragments of S, covering the entire ectodomain (amino acids 48 to 1192), as glutathione S-transferase
fusion proteins in Escherichia coli and used the purified proteins to raise antibodies in rabbits. By Western blot
analysis and immunoprecipitation experiments, we showed that all the antibodies are specific and highly
sensitive to both the native and denatured forms of the full-length S protein expressed in virus-infected cells
and transfected cells, respectively. Indirect immunofluorescence performed on fixed but unpermeabilized cells
showed that these antibodies can recognize the mature form of S on the cell surface. All the antibodies were
also able to detect the maturation of the 200-kDa form of S to the 210-kDa form by pulse-chase experiments.
When the antibodies were tested for their ability to inhibit SARS-CoV propagation in Vero E6 culture, it was
found that the anti-S10 antibody, which was targeted to amino acid residues 1029 to 1192 of S, which include
heptad repeat 2, has strong neutralizing activities, suggesting that this region of S carries neutralizing epitopes
and is very important for virus entry into cells.
A novel coronavirus (CoV) was identified as the etiological
agent of severe acute respiratory syndrome (SARS) (8, 9, 15,
20). CoVs are positive-strand RNA viruses, and the virion
consists of a nucleocapsid (N) core surrounded by an envelope
containing three membrane proteins, spike (S), membrane
(M), and envelope (E), that are common to all members of the
genus (for reviews, see references 16 and 24). The S protein,
which forms morphologically characteristic projections on the
virion surface, binds to host receptors and mediates membrane
fusion. The M and E proteins are important for viral particle
assembly, while N is important for viral RNA packaging.
The S protein of CoV is a type 1 integral membrane glyco-
protein. It is cotranslationally glycosylated and oligomerized at
the endoplasmic reticulum. Its N-linked high-mannose side
chains are trimmed and modified and become endoglycosidase
H (EndoH) resistant during the transportation to the Golgi
apparatus. For some but not all CoVs, the S protein is cleaved
into the N-terminal S1 and C-terminal S2 subunits, which con-
tain receptor binding and membrane fusion domains (10, 32),
respectively. The mature forms of S are assembled into virions,
which release from infected cells. A portion of S is transported
to the plasma membrane, resulting in cell-cell fusion or for-
mation of syncytia. The S protein belongs to the class 1 viral
fusion proteins and contains two heptad repeat domains (HR1
and HR2) in S2 or the C-terminal region. These two domains
interact and play a crucial role in mediating virus-cell mem-
brane fusion and entry of virus into cells.
The S protein of CoV is known to be responsible for induc-
ing host immune responses and virus neutralization by anti-
bodies (5, 7, 14, 25). For SARS-CoV, it has been demonstrated
that prior infection provided protective immunity in a mouse
model and that the passive transfer of neutralizing antibodies
to naive mice also protected them from infection (26). This
suggests that neutralizing antibodies have an important role in
reducing the viral load or preventing viral replication. A DNA
vaccine encoding the S protein alone induces T-cell and neu-
tralizing antibody responses and protected mice from SARS-
CoV infection (34), suggesting that the S protein is indeed the
primary target for viral neutralization in SARS-CoV infection.
This finding was also confirmed by at least four independent
studies that use a carrier virus to express S in mice or primates
(2, 5, 6, 11). These reports highlight the potential for develop-
ing peptide-based vaccine candidates if neutralizing epitopes
of S could be identified.
In this study, we aim to identify neutralizing epitopes in the S
protein of SARS-CoV, which may be used for the development
of vaccine or therapeutic agents against SARS-CoV infection.
We expressed different regions of S as glutathione S-transfer-
ase (GST) fusion proteins and used them to raise antibodies in
rabbits. These polyclonal antibodies were then tested for their
specificities for the native and denatured forms of S in Western
blot, immunoprecipitation, and immunofluorescence analyses
as well as for their capacities to inhibit SARS-CoV replication
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in Vero E6 culture. A novel neutralizing epitope in S2 con-
taining HR2 was identified.
MATERIALS AND METHODS
Cells and viruses. The monkey kidney cell lines Cos7 and Vero E6, used in this
study, were purchased from the American Type Culture Collection (Manassas,
Va.). Cos7 and Vero E6 cells were cultured at 37°C in a 5% CO2 incubator in
Dulbecco modified Eagle medium containing 0.1 mg of streptomycin/ml, 100 U
of penicillin/ml, and 10% fetal bovine serum (HyClone, Logan, Utah). SARS-
CoV viral strain Sin2774 (GenBank accession no. AY283798) (22) and recom-
binant vaccinia virus vTF7-3 expressing bacteriophage T7 RNA polymerase were
grown in Vero E6 cells.
Construction of plasmids. (i) Plasmids for expression in mammalian cells.
Viral RNA of Singapore strain Sin2774 was extracted and used for amplification
of the S gene by reverse transcription-PCR (RT-PCR) with specific primers. The
PCR products were digested with BamHI and StuI and ligated into BamHI/
EcoRV-cut pKT0, resulting in plasmid pKT-S under the control of a T7 pro-
moter. Specific primers were designed to amplify a strain Sin2774 sequence from
nucleotide positions 21476 to 25171, 25066, 24934, 24415, 24157, and 23866. The
six RT-PCR products were digested with BamHI and StuI and ligated to BamHI/
EcoRV-cut pKT0 under the control of a T7 promoter, giving rise to plasmids
pKT-S11, pKT-S12, pKT-S13, pKT-S14, pKT-S15, pKT-S16, respec-
tively. These constructs encode the C-terminally truncated S proteins, as shown
in Fig. 1.
(ii) Plasmids for expression in Escherichia coli. Five PCR fragments encoding
the S1, S2, S3, S9, and S10 fragments (Fig. 1) were obtained with the
primers listed in Table 1. All primers used were purchased from Research
Biolabs or Proligo Pte Ltd. (Singapore). The PCR products were digested by
BamHI/XhoI and ligated into the BamHI/XhoI-cut pGEX4T1 vector (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) to obtain plasmids pGEX-S1,
pGEX-S2, pGEX-S3, pGEX-S9, and pGEX-S10 for the expression of GST
fusion proteins (Fig. 1). The GST tag was located at the N terminus of the fusion
protein.
Purification of the recombinant S proteins expressed in E. coli. Plasmids
pGEX-S1, pGEX-S2, pGEX-S3, pGEX-S9, and pGEX-S10 were sepa-
rately transformed into BL21(DE3) cells. A single colony from each plate was
grown at 37°C overnight in Luria-Bertani (LB) medium containing ampicillin
(100 g/ml). Five milliliters of the resulting cultures was inoculated into 2 liters
of LB medium containing ampicillin (100 g/ml), which was incubated in a
shaker at 37°C until the optical density at 600 nm reached 0.6. Expression of
proteins was induced with 1 mM IPTG (isopropyl--D-thiogalactopyranoside).
Cells were harvested 2 h after induction by centrifugation at 5,000  g for 10 min
at 4°C. The cell pellets obtained were resuspended in phosphate-buffered saline
(PBS)–1 mM phenylmethylsulfonyl fluoride–20 g of DNase I/ml and lysed by
two passages through a French press. Lysates were centrifuged at 22,000  g for
30 min. The insoluble proteins in the pellet were washed three times and resus-
pended in PBS containing 1% Triton X-100. Proteins were separated in sodium
dodecyl sulfate–10% polyacrylamide gel electrophoresis (SDS-10% PAGE) gels.
Gel strips containing GST fusion proteins were cut, and the proteins were eluted
with a Mini Trans-Blot cell (Bio-Rad, Hercules, Calif.). The resulting fusion
proteins were detected by Western blotting with mouse anti-GST antibodies
(Santa Cruz Biotechnology, Santa Cruz, Calif.), and their concentrations were
estimated by comparison with bovine serum albumin standards in a Coomassie
brilliant blue R-250 (Bio-Rad)-stained SDS-PAGE gel.
Generation of antibodies against the various GST-S fusion proteins. One
milligram of each of the proteins S1, S2, S3, S9, and S10 was mixed with
an equal volume of complete Freund’s adjuvant (Sigma, St. Louis, Mo.) and used
for the immunization of New Zealand White rabbits. Two rabbits were used to
raise antibodies against each respective antigen. Three weeks after the initial
immunization, the rabbits were given booster injections at 2-week intervals.
Incomplete Freund’s adjuvant (Sigma) was used for subsequent booster injec-
tions. Ten milliliters of blood was harvested from the rabbits each time after the
4th, 6th, 8th, 12th, 14th, and 16th injections. All procedures for the use of
laboratory animals were done in accordance with the regulations and guidelines
of Animal Research Ethics Committee.
Expression of recombinant S proteins in mammalian cells. Cos7 cells were
used as the mammalian expression system, and the resulting S proteins were used
for Western blotting, immunoprecipitation, and indirect immunofluorescence
analysis. Monolayers of Cos7 cells, grown in a 21-cm2 dish were subjected to
vTF7-3 vaccinia virus infection at a multiplicity of infection (MOI) of 1 PFU per
cell. Transient transfections of cells with pKT-S, pKT-S11, pKT-S12, pKT-
S13, pKT-S14, pKT-S15, and pKT-S16 plasmids were carried out at 1 h
postinfection with Effectene transfection reagents (QIAGEN, Valencia, Calif.)
according to the manufacturer’s protocol as previously described (S. Shen et al.,
submitted for publication). For control experiments, cells were infected with the
vTF7-3 vaccinia virus and mock transfected with the empty vector pKT0.
Western blot analysis. Cos7 cells were infected with 1 PFU of vTF7-3 vaccinia
virus/cell for 1 h and transfected with pKT-S as described above. Cell lysates were
prepared with 1 SDS loading buffer under reducing conditions (60 mM Tris-
HCl [pH 6.8], 1% SDS, 20 mM dithiothreitol, 10% glycerol, 0.02% bromophenol
blue). Proteins were separated in 10% PAGE gel and transferred to a nitrocel-
FIG. 1. Schematic diagram showing the different regions of S en-
coded by the plasmids used in this study. (Top) Regions (arrows)
representing the five bacterially expressed proteins (S1, S2, S3,
S9, and S10) used to raise the antibodies. The numbers at each end
of the arrows represent the positions of the amino acid residues in the
S protein. , anti. (Bottom) Full-length S and the S proteins with
C-terminal deletions (S11 to S16) were expressed in Cos7 cells.
Numbers at the end of the proteins represent the positions of amino
acid residues of the respective proteins. Heptad repeat regions HR1
(aa 891 to 975) and HR2 (aa 1148 to 1193) are shown.
TABLE 1. Primers used in this study
Primer Sequencea Application
SS03-56 5-ACGGATCCACCATGTTTATTTTCTTATTA-3 Cloning full-length S
SS03-57 3-GTAGGCCTATGTGTAATGTAATTTGAC-5 Cloning full-length S
SS03-62 5-AAGGATCCAGATCAGACACTCTTTATTT-3 Cloning S1
SS03-63 3-AAAATCTCGAGTTGTAGAGCACAGAG-5 Cloning S1
SS03-60 5-CAGGATCCTCAACCTTTAAGTGCTATG-3 Cloning S2
SS03-61 3-CTATCTCGAGTCAGGTAATATTTGTGAAA-5 Cloning S2
SS03-68 5-CTGGATCCTTTTCGCTTGATGTTTC-3 Cloning S3
SS03-69 3-TATTACTCGAGGGAGAAAGGCACATT-5 Cloning S3
SS03-101 5-CTGGATCCTCTTTTATTGAGGACTTGC-3 Cloning S9
SS03-102 3-TGAACTCGAGCTCCTGGGATGGCACAT-5 Cloning S9
SS03-103 5-AGGGATCCCACCTTATGTCCTTCC-3 Cloning S10
SS03-104 3-AAACCTCGAGAGGCCATTTAATATATTGC-5 Cloning S10
a Restriction sites introduced into primers are shown in bold face.
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lulose membrane. The membranes were blocked in 5% nonfat milk in PBS with
0.05% Tween 20 and probed with rabbit antisera (1:10,000 to 1:60,000) raised
against the various S fusion proteins at 4°C overnight. The membranes were
incubated with preimmune sera (1:4,000) as controls. The membranes were
incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary
antibodies (Pierce, Rockford, Ill.) at a dilution of 1:2,000 for 1 h at room
temperature and developed with enhanced chemiluminescence reagent (Pierce).
When a SARS patient’s serum (P6) was used, it was diluted 1:200 and the
secondary antibody was diluted 1:2,000. For loading control, membranes were
stripped with stripping buffer (2% SDS, 100 mM -mercaptoethanol, 62.5 mM
Tris-HCl [pH 6.8]) for 30 min at 65°C and washed extensively with PBS-Tween
20 before being reprobed with a mouse anti--actin antibody (Sigma) at a
dilution of 1:3,000.
Radiolabeled immunoprecipitation. Cos7 cells were infected with vaccinia
virus vTF7-3 and transfected with pKT-S or plasmids expressing the S C-terminal
deletion mutant proteins (pKT-S11, pKT-S12, pKT-S13, pKT-S14, pKT-
S15, and pKT-S16) as described above. Cells were mock transfected with
pKT0 as controls. At 3 h posttransfection, the cells were starved for 30 min with
methionine-cysteine (Met-Cys)-free medium before being labeled with [35S]Met-
Cys for 1 h and chased with 4 mM cold Met-Cys for 2 h. For the time course
experiment, the chase periods before harvesting the cells were 0, 1/2, 1, 2, 4, and
6 h. For virus-infected Vero E6 cells, cells were infected at a MOI of 5, radio-
labeled at 5 h postinfection for 1 h, and chased for 3 h. Cells were lysed with lysis
buffer containing 150 mM NaCl, 20 mM Tris (pH 7.5), 1% NP-40, 5 mM EDTA,
1 mM phenylmethylsulfonyl fluoride and centrifuged at 16,000  g for 10 min. A
portion of the supernatant (300 l) was incubated for 1/2 h with 5 l of
antiserum, followed by a 1-h incubation with protein A-Sepharose beads (Roche
Diagnostics). The beads were washed three times with lysis buffer. Twenty mi-
croliters of 1 SDS loading buffer was added to the beads and boiled for 5 min
at 100°C. For the EndoH treatment, the beads were resuspended in EndoH
buffer provided by the manufacturer and the immunoprecipitated proteins were
eluted by boiling for 5 min. Samples were treated with EndoH enzyme (Roche
Diagnostics) at 37°C for 2 h. For the control, samples were treated in the same
manner except no enzyme was added. All the samples were separated in a
SDS–7.5% PAGE gel and visualized by autoradiography.
Indirect immunofluorescence. Cos7 cells grown on Permanox slide (Nalge
Nunc International, Naperville, Ill.) were infected and transfected as described
above. At 8 h posttransfection, cells were fixed with 4% paraformaldehyde for 10
min at room temperature and blocked with PBS containing 1% bovine serum
albumin for 30 min; they were then incubated with the primary antibody (1:200)
for 1.5 h, washed, and incubated with the fluorescein isothiocyanate-conjugated
secondary antibody (1:200; Santa Cruz Biotechnology) for 1 h. All incubations
and washes were performed at room temperature. Slides were mounted with
fluorescence mounting medium (Dako Cytomation) and analyzed on an Axio-
Vision fluorescence light microscope (Carl Zeiss Vision GmbH, Hallbergmoss,
Germany).
Neutralization assay. To determine the neutralizing activities of the rabbit
antisera, we performed a neutralization assay using a 96-well plate. Vero E6 cells
(2  104) were grown in 200 l of medium in each well of the 96-well plates and
incubated at 37°C. Serial dilutions of rabbit sera with the medium in ratios of 1:10
to 1:1,280 were prepared. Diluted rabbit antisera (0.1 ml) were mixed with 0.1 ml
of SARS-CoV at 200 (or 1,000) 50% tissue culture infective doses (TCID50) for
1 h at 37°C before being added into the respective wells. At each dilution,
antiserum and virus mixtures were added to eight wells. The 96-well plate was
incubated in a CO2 incubator for 4 days to observe the cytopathic effect. The
ratios of infected wells to uninfected wells were determined under microscopy.
The titers of the neutralizing antibodies were calculated by the Reed-Muench
method (21) and expressed as TCID50 per 0.1 ml. All experiments were carried
out in duplicate.
RESULTS
Generation of rabbit antibodies against the different regions
on the S protein. Previous studies have shown that antibodies
targeting bacterially expressed amino acids (aa) 548 to 567, 607
to 627 (37), and 803 to 828 (36) of S exhibit some neutraliz-
ing activities. We aim to identify the neutralizing regions that
could elicit strong neutralizing antibodies. To determine the
neutralizing regions on the bacterially expressed SARS-CoV S
protein, we expressed five fragments of S covering the entire
ectodomain (Fig. 1). Two fragments covered the S1 region
(S1 and S3), two fragments covered the S2 region (S9 and
S10), and one fragment covered a portion of both S1 and S2
(S2). S9 and S10 contain the HR1 and HR2 regions,
respectively. Antigens for S1, S2, S3, S9, and S10 were
injected into rabbits to raise polyclonal antibodies against their
respective target regions. The immunizations were carried out
as mentioned in Materials and Methods. Multiple booster in-
jections were performed in an attempt to increase the titers
and specificity of antibodies. The specificity and sensitivity of
the antisera were determined after each bleed by Western
blotting and immunoprecipitation (data not shown).
Detection of denatured form of SARS-CoV S protein by
Western blotting. The sensitivities of the antibodies and their
specificities for the full-length S protein, expressed in mamma-
lian Cos7 cells, were determined by Western blot analysis. As
postulated, anti-S antibodies from the serum of a patient (P6)
who has recovered from SARS-CoV infection (28) could de-
tect two major bands of full-length S protein, the 140-kDa un-
glycosylated form and the 200-kDa glycosylated form (Fig. 2,
lane 1), in the lysates of Cos7 cells transfected with the full-
length S plasmid, pKT-S. These are specific S bands, as they
were not detected in mock-transfected cells (lane 2) and by
serum from a healthy donor (lanes 13 and 14). We observed
similar results using the antibodies that we raised against the
five S fusion proteins (Fig. 2, lanes 3, 5, 7, 9, and 11). No
specific bands were detected in mock-transfected cells (lanes 4,
6, 8, 10, and 12) and by preimmune sera from the same rabbits
(lanes 15 to 24). The results indicate that all the antibodies
raised against the various S fragments could specifically bind to
S in denaturing condition by targeting different regions of the
linearized S protein. Therefore, these antibodies are specific to
the denatured full-length SARS-CoV S protein.
Detection of the undenatured form of S in transfected cells.
To determine the specificities of the antibodies for the unde-
natured form of the S protein and their respective target re-
gions on the S protein, we carried out immunoprecipitation
experiments using the various antibodies. Lysates of Cos7 cells
infected with vTF7-3 vaccinia virus and transfected with pKT-S
and plasmids encoding the mutant proteins with C-terminal
deletions, pKT-S11, pKT-S12, pKT-S13, pKT-S14, pKT-
S15, and pKT-S16, were immunoprecipitated with P6 serum
and the five antibodies raised against the S1, S2, S3, S9,
and S10 regions. The SARS-CoV full-length S protein and
the proteins with C-terminal deletions can be detected by im-
munoprecipitation with the P6 serum (Fig. 3f). As expected,
the sizes of the S proteins with deletions in the C terminus
decrease from S11 to S16, as more amino acid residues were
removed from the C terminus. Two forms of S (200 and
210 kDa) were detected in cell lysates transfected with the
full-length S construct (Fig. 3a to f, lanes 1). These might
represent the mature and immature forms of the full-length S
protein. Antibodies targeting regions S1, S2, and S3 indi-
vidually can detect the full-length S and all the proteins with
C-terminal deletions (Fig. 3a to c). Antibodies targeting region
S9 can detect full-length S and S11 to S15 proteins. No
specific band was detected in the S16 lane because S16 does
not contain the S9 region (Fig. 3d). Antibodies targeting
S10 could only detect the protein bands expressed by pKT-S
and pKT-S11 to pKT-S13 (Fig. 3e). The regions expressed
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by pKT-S14, pKT-S15, and pKT-S16 do not include the
S10 region and thus rabbit anti-S10 does not detect any
band in these lanes, showing that these antibodies are highly
specific to their target regions. The conformation of the S
protein was retained in the nondenaturing lysis buffer in im-
munoprecipitation, and the results showed that the protein
possesses an epitope(s) which can be recognized by all five
antibodies raised against the five fusion proteins. The 140-kDa
unglycosylated form of S was not detected by immunoprecipi-
tation with any of the antibodies used. The results suggested
that either the unglycosylated S protein was not recognized by
these antibodies under nondenaturing conditions or the 140-
kDa form of S did not accumulate in pulse-chase experiments.
Detection of the native S protein in virus-infected cells and
cultured media. To further investigate whether these poly-
clonal antibodies can specifically bind to the native S protein,
the S proteins synthesized in virus-infected cells and released
as components of the virion to cultured medium were analyzed
FIG. 2. Western blot analysis for detection of the S protein. Cos7 cells were transfected with plasmid pKT-S (lanes 1, 3, 5, 7, 9, 11, 13, 15, 17,
19, 21, and 23) or with a plasmid without an insert as a negative control (lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). Cell lysates were separated
in 10% PAGE gel. Western blotting was performed with the antisera, preimmune sera, and control serum indicated on top of each gel. Arrowheads
(left), molecular masses (in kilodaltons) of specific S proteins. Membranes were reprobed with mouse anti--actin as the loading control.
High-range Rainbow molecular weight markers (right; Amersham) were used. , anti.
FIG. 3. Radiolabeled immunoprecipitation. Cos7 cells were transfected with plasmids expressing full-length S and the C-terminally truncated
S proteins, S11, S12, S13, S14, S15, and S16 (lanes 1, 2, 3, 4, 5, 6, and 7) or with a plasmid without an insert as a negative control (lanes
8). 35S-labeled S proteins were immunoprecipitated with the antibodies indicated (top of each autoradiograph) and then separated in SDS–7.5%
PAGE gels. Arrowheads (left), molecular masses (in kilodaltons) of specific S proteins. High-range Rainbow molecular weight markers (right;
Amersham) were used. , anti.
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in an immunoprecipitation assay using the lysis buffer de-
scribed above. As shown in Fig. 4a, a specific S protein was
detected in both cell lysates (top, lanes 2, 6, and 10; bottom,
lanes 2 and 6) and media (top, lanes 4, 8, and 12; bottom, lanes
4 and 8). The S protein was not detected in cells and media of
mock-infected cells (lanes 1, 3, 5, 7, 9, and 11) or in infected
cells and medium using preimmune serum of a rabbit immu-
nized with the S10 peptide (immunoprecipitations using
other preimmune sera were negative and are not shown). It
was noted that the S species in media is slightly larger than
majority of S species in cell lysates, suggesting (i) that the S
protein had matured from 200 to 210 kDa and (ii) that the
mature and modified S protein of 210 kDa was assembled into
a virion. The results confirmed that these antibodies are spe-
cific for the native S protein in virus-infected cells and virus
particles.
Maturation of the 200-kDa S protein to the 210-kDa EndoH-
resistant form. Two S-specific bands were observed in the
immunoprecipitation experiments. We suspect that the 210-
kDa band was the mature glycosylated S protein and that the
200-kDa band is the immature glycosylated S protein. To in-
vestigate the maturation of S, we carried out a pulse-chase
labeling experiment. Cos7 cells infected with vaccinia virus
vTF7-3 and transfected with pKT-S were radiolabeled with
[35S]Met-Cys and chased with cold Met-Cys for 1/2, 1, 2, 4, and
6 h, followed by immunoprecipitation with rabbit anti-S10.
The results showed a gradual increase in the 210-kDa band
accompanied by a gradual decrease in the 200-kDa band (Fig.
4b, lanes 1 to 8). The yields of 200- and 210-kDa proteins
decreased after chasing for 4 h due to cell death caused by
vTF7.3 infection; however, the ratio of 210- to 200-kDa protein
increased. Immunoprecipitation was performed with all the
other antisera (rabbit anti-S1, anti-S2, anti-S3, and anti-
S9), and the same results were obtained (data not shown). To
provide more evidence to support our findings, an EndoH
treatment experiment was carried out to find out whether the
bands were sensitive to EndoH. The radiolabeled cell lysates
described above were immunoprecipitated with rabbit anti-
S10 and treated or mock treated with EndoH enzyme. Re-
sults showed that the 210-kDa band was EndoH resistant and
that the 200-kDa band was EndoH sensitive (Fig. 4b, lanes 9
and 10). Hence, the results demonstrated the maturation of the
200-kDa band to the 210-kDa band. Other antibodies (rabbit
anti-S1, anti-S2, anti-S3, and anti-S9) can also recognize
both the mature and immature forms of the S glycoprotein
(data not shown).
Detection of SARS-CoV S protein on surfaces of Cos7 cells.
To provide further evidence that the antibodies raised against
the five fusion proteins were able to recognize the S protein, we
performed indirect immunofluorescence experiments under
nonpermeabilized conditions. After infection with the vTF7-3
vaccinia virus and transfection with pKT-S, sufficient time (8 h
posttransfection) was allowed for the S protein to be expressed
and transported to the cell surface. The mature S protein could
exist in trimeric or oligomeric form on the cell surface, and
these could be clearly detected with any of the antibodies
raised against the various S proteins (Fig. 5, left). The binding
of the antibodies against S1, S2, S3, S9, and S10 to the
S protein on the cell surface suggests that these antibodies
might recognize the properly folded, mature form of the
SARS-CoV S protein, which was expressed and transported to
the cell surface. The experiment was repeated three times, and
all the results were consistent.
A region in S2 can elicit neutralizing activity. After deter-
mining that all the antibodies could recognize the native form
of the SARS CoV S protein, we tested their neutralizing ac-
FIG. 4. (a) Immunoprecipitation of the S protein in cell lysate and
medium of virus-infected Vero E6 cells. Vero E6 cells in 60-mm dishes
were infected (lanes 2, 4, 6, 8, 10, and 12) with SARS-CoV at a MOI
of 5 or mock infected (lanes 1, 3, 5, 7, 9, and 11). Cells were radiola-
beled 5 h postinfection with [35S]Met-Cys for 1 h. Cells were chased
with medium containing 4 mM Met-Cys for 3 h. Cells (lanes 1, 2, 5, 6,
9, and 10) and media (lanes 3, 4, 7, 8, 11, and 12) were harvested with
1 or 1/5 volume of 5 lysis buffer, respectively. Samples were im-
munoprecipitated with antisera and preimmune serum as indicated
and then separated in SDS–7.5% PAGE gels. The S-specific bands are
indicated on the right. High-range Rainbow molecular weight markers
(left; Amersham) were used. Rb, rabbit; , anti. (b) Time-course of S
protein maturation. Cos7 cells transfected with pKT-S were radiola-
beled and chased for 0, 0.5, 1, 2, 4, and 6 h (lanes 1, 2, 3, 4, 5, 6, and
7). Cos7 cells transfected with a plasmid without an insert were har-
vested at 6 h as a negative control (lane 8). All the cell lysates were
immunoprecipitated with rabbit anti-S10 antibodies and then sepa-
rated in SDS–7.5% PAGE gels. In a separate experiment, the immu-
noprecipitated proteins (6 h posttransfection) were treated () with
EndoH (lane 10) or untreated (	) as a control (lane 9). The S-specific
bands and their molecular masses (in kilodaltons) are indicated on
the right. High-range Rainbow molecular weight markers (left; Amer-
sham) were used.
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tivities. All antisera from rabbits injected with the various S
proteins were tested for their neutralizing activities after each
bleed. Results for rabbits injected with bacterially expressed
S1, S2, S3, and S9 showed negative response. Sera from
rabbits injected with S10 showed neutralizing activities after
the fourth injection but not the preimmune sera from the same
rabbits. Initial tests using SARS-CoV at 200 TCID50/well
showed high titers (1:364) of neutralizing antibodies in all the
anti-S10 antisera, beginning with serum bled after the 8th
injection (Table 2). The 16th injection was the last booster
injection, and the rabbit was sacrificed at this stage. The neu-
tralizing titer was comparable to, if not higher than, the titers
detected in SARS patients. The antibody response in SARS
patients at 100 TCID50/well ranges from 1:150 to 1:475 over a
period of 210 days (23). To ascertain the results above, serum
samples after the 4th, 6th, 8th, 12th, 14th, and 16th injections
with S10 were used for neutralizing tests using SARS-CoV at
1,000 TCID50/well (Table 3). Neutralizing activities were found
to be as high as 1:189.2 at l,000 TCID50/well. This result
showed that the S10 fragments expressed in E. coli covering
amino acid residues 1055 to 1192 can stimulate neutralizing
antibodies but that those fragments covering all other regions
of the ectodomain of S cannot. It was interesting that S10 (aa
1055 to 1192), which contained the HR2 domain, could elicit a
strong neutralizing response but not S9 (aa 798 to 1055),
which covered the HR1 domain. S1, S2, S3, and S9 could
possess neutralizing epitopes that are conformation or glyco-
sylation dependent and could have their epitopes impaired in
the bacterial expression system, which explains their lack of
neutralizing activity.
DISCUSSION
The S protein of CoV is an important determinant of tissue
tropism, as it binds to cellular receptors on the host cell and
as it also mediates virus and cellular membrane fusion. For
SARS-CoV, it appears that neutralizing antibodies against S
can provide some form of immunity against SARS-CoV infec-
tion (2, 5, 6, 12, 27). In this study, we raised rabbit polyclonal
antibodies against five bacterially expressed S fragments, cov-
ering the entire ectodomain (aa 48 to 1192). As these proteins
were expressed in E. coli, the antibodies might not be able to
recognize some conformation- or glycosylation-dependent neu-
tralizing epitopes on S. Our analysis is also likely to be limited
to linear epitopes since the proteins were extracted from SDS
denaturing gels and eluted in the presence of SDS, although
we cannot rule out the possibility that the protein can maintain
FIG. 5. S protein expressed on the surfaces of transiently trans-
fected Cos7 cells. (Left column) Cos7 cells were transfected with full-
length S and visualized under UV light. The green fluorescence repre-
sents the S protein expressed on the surfaces of Cos7 cells probed with
primary antibodies rabbit anti-S1 (-S1), anti-S2, anti-S3, anti-
S9, and anti-S10, followed by fluorescein isothiocyanate-conjugated
secondary antibodies. (Right column) Cos7 cells were mock trans-
fected with the empty vector and probed with the antibodies indicated
on the left, as control experiments, and visualized under UV light.
TABLE 2. Neutralizing tests at 200 TCID50 per well
a
No. of injections
before bleeding
Neutralizing titerb
(avg of 2 expt)
0 (preimmune serum).............................................................. 0
8.................................................................................................. 70
12.................................................................................................. 364
14.................................................................................................. 208
16.................................................................................................. 256
a Neutralizing tests were done using a 96-well plate at 200 TCID50 per well.
b Determined by the Reed-Muench method.
TABLE 3. Neutralizing tests at 1,000 TCID50 per well
a
No. of injections
before bleeding
Neutralizing titerb
(avg of 2 expt)
0 (preimmune serum) ............................................................ 0
4 ................................................................................................ 30
6 ................................................................................................ 66.8
8 ................................................................................................ 112
12 ................................................................................................ 67.2
14 ................................................................................................ 98
16 ................................................................................................ 189.2
a Neutralizing tests were done using a 96-well plate at 1,000 TCID50 per well.
b Determined by the Reed-Muench method.
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some degree of folding. Interestingly, we found that the anti-
bodies not only were able to recognize denatured S proteins
(expressed in mammalian cells) in Western blot analysis but
also could immunoprecipitate native S proteins from cell ly-
sates (or media) of transfected and virus-infected cells (Fig. 2
and 4a). The results indicate that these antibodies bind to
linear and exposed epitopes present in the folded S and/or to
flexible regions, such as turns, that exist in the structure of S.
Importantly, immunoprecipitation experiments showed that
these antibodies could bind to both the EndoH-sensitive, gly-
cosylated (200-kDa) full-length S and the EndoH-resistant gly-
cosylated S (210 kDa). This is also supported by indirect im-
munofluorescence experiments which showed that these
antibodies could recognize S protein expressed on the cell
surface. It is known that the glycosylated S protein has to be
transported to the Golgi apparatus before it undergoes matu-
ration and that it is then transported to the cell surface (19,
31). We found that maturation of the S protein of SARS-CoV
results in an increase in apparent molecular mass from 200 to
210 kDa. It is also shown that the 210-kDa fully glycoslyated
form of SARS CoV S is later incorporated into virions which
are released into the medium of SARS-CoV-infected Vero E6
culture (Fig. 4a).
Neutralization assays showed that antibodies raised against
GST-S10 were capable of neutralizing SARS-CoV replica-
tion in Vero E6 cells at a titer of up to 1:364 at 200 TCID50,
which is comparable to the level obtained for convalescent
patients (23). Analysis of sera taken after accumulative immu-
nizations displayed a steady increase in neutralizing titer, in-
dicating that the immunized rabbits showed a specific immune
response to GST-S10. None of the other antigens was capa-
ble of inducing neutralizing antibodies, which could indicate
that there was an absence of neutralizing epitopes in aa 48 to
1055 of the S protein. However, this phenomenon is most
unlikely, as a human antibody against aa 261 to 672 has been
shown to have neutralizing properties (27) (see below for a
discussion of the receptor binding domain). The more proba-
ble explanation is that neutralizing epitopes in this region are
heavily glycoslyated and/or contain rigid tertiary structures.
Therefore, our results showed that aa 48 to 1055 of the S
protein are not suitable for use in the development of vaccines
that are peptide based or based on proteins expressed in non-
mammalian systems that are not able to mimic the glycoslya-
tion process or proper folding in mammalian cells.
The first step in CoV infection is the attachment of virions to
host cells, and, for SARS-CoV, ACE-2 has been identified as
the cellular receptor that binds to the SARS-CoV S protein
(17). A domain in the N terminus of the S protein, approxi-
mately aa 300 to 510, is the receptor binding domain (1, 32,
33). Subsequently, the fusion of the lipid bilayer of the viral
envelope with the host cell membrane is mediated by an inter-
nal fusion peptide of S (4, 10). The CoV S protein is a class I
virus fusion protein and contains two heptad repeat domains
(HR1 and HR2) in S2 or the C-terminal region. These do-
mains are postulated to play crucial roles in defining the oli-
gomeric structure of S and hence facilitate the fusion between
viral and cellular membranes (10). For SARS-CoV, HR2 is
located close to the transmembrane anchor (aa 1195 to 1223)
and HR1 is 170 aa upstream of it (aa 891 to 975) (13).
Interestingly, S10 (aa 1029 to 1192) encompasses the HR2
region, and our results are consistent with the findings of sev-
eral other laboratories that peptides from the HR2 region can
block SARS-CoV infection (4, 35, 38). A peptide containing
HR2 can potentially be developed as a therapeutic reagent for
treatment of SARS-CoV infection (4). We found that a pep-
tide containing HR2 (S10) is a potential vaccine candidate
and would be suitable for subunit vaccine development.
Biochemical studies have shown that peptides corresponding
to the HR1 and HR2 of the SARS-CoV S protein can associate
into an antiparallel six-helix bundle with structural features
typical of those of the other known class I fusion proteins,
suggesting that the membrane fusion and cell entry mecha-
nisms exploited by SARS-CoV are similar to those for other
CoVs, such as mouse hepatitis virus (3, 13, 18, 30, 35, 38). In
the full-length S protein, the HR1-HR2 structure brings the
fusion peptide, predicted to be near the N terminus of HR1
(4), into close proximity to the transmembrane domain, and
this facilitates the fusion between viral and cellular mem-
branes, allowing the virus to enter the cell. It is very probable
that, by binding to the HR2 domain with high affinity, anti-
S10 antibodies could block the interaction between HR1 and
HR2 and hence prevent SARS-CoV fusion with the host cells.
As bacterially expressed proteins would be easy and cost-
effective to produce on a large scale, the S10 fragment (aa
1029 to 1192) identified in this study may be an ideal vaccine
candidate for SARS-CoV. In future studies, it will be critical to
determine if the immunization of peptide S10 can prevent
SARS-CoV replication and, more importantly, prevent disease
in animal models. It is also important to delineate the precise
contribution of this S region to membrane fusion. We are
currently mapping monoclonal antibodies obtained from mice
that have been immunized with GST-S10 proteins and deter-
mining their binding and neutralizing properties. Last, the re-
combinant S10 protein and anti-S10 antibodies can poten-
tially be developed for antiviral treatments, as it has recently
been shown to be possible to control SARS-CoV infection in
ferrets with a neutralizing antibody directed against S (29).
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